Grifols Rises as Exane Foresees Plasma Price Jump: Madrid Mover
This article is for subscribers only.
Grifols SA, Europe’s largest maker of blood-plasma products, jumped the most in seven months after Exane BNP Paribas said the global market for protein therapies derived from the material will expand in the next two years.
Grifols rose 4 percent to close at 28.45 euros in Madrid, the biggest advance since Sept. 21, leading gains on the 35-stock Stoxx 600 Health Care Index. The number of shares traded was about 1.3 times the three-month daily average.